HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global

— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall...

Related Keywords

China ,Australia ,Japan ,Shanghai ,United States ,Japanese ,Chinese ,American ,Marek Kania ,Eli Lilly ,Fruquintinib Development Beyond ,International Corporation ,Drug Administration ,Nasdaq ,Journal Of The American Medical Association ,China Limited ,China National Medical Products Administration ,Japanese Pharmaceuticals ,European Medicines Agency ,China National Reimbursement Drug List ,Devices Agency ,Managing Director ,Chief Medical Officer ,Medical Devices Agency ,Fast Track Designation ,Drug Application ,Fruquintinib Approval ,American Medical Association ,Nasdaq Hcm ,Hutchmed China Limited ,